Vanguard Asset Management
PCRX icon

Vanguard Asset Management’s Pacira BioSciences PCRX Stock Holding History

Vanguard Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$671K Hold
26,450
– – ﹤0.01% 2070
2026
Q1 		$598K Buy
+26,450
New +$588K ﹤0.01% 2009

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's PCRX Position: Q2 2026 in Review

Vanguard Asset Management held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 26,450 shares worth $671K. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Vanguard Asset Management first reported a position in PCRX in Q1 2026 and has held it in 2 quarters since. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Vanguard Asset Management held 26,450 shares of Pacira BioSciences worth $671K as of Q2 2026.
  • Vanguard Asset Management left its Pacira BioSciences share count unchanged in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2070 holding.
  • Vanguard Asset Management first reported a position in Pacira BioSciences in Q1 2026 and has held it in 2 quarters since.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.